ArticleScientific reports2025
A rice SOUL family heme-binding protein REAC1 enhances the antioxidative capacity of C. elegans through modulation of ROS-related gene expression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The development and identification of beneficial components from crop resources are vital for individuals, especially the elderly, as they are capable of facilitating health. Red rice is widely consumed and possesses potential therapeutic effects to some extent, but it is important to discover the specific roles of each component when consumed purposefully. In this context, the REAC1/rHBP2, a red rice heme-binding protein (HBP) from the SOUL family, was revealed that possesses a role in boosting the antioxidative capacity of C. elegans that consume this protein. The Arabidopsis plants overexpressing REAC1 presented more tolerance to oxidative stress related to the wild-type plants. Furthermore, REAC1 derived from engineered bacteria exhibited clear activities of heme-binding and hydroxy radical inhibition in vitro. While no adverse effects were observed in the nematodes that were treated with REAC1, they exhibited enhanced motility and improved survival under oxidative conditions simulated by treatment with 5 mM H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.